Skip to main content
Clinical Trials/DRKS00005154
DRKS00005154Not yet recruitingNot Applicable

Observational Study for the Outcome After Discontinuing TNF Blockers in Crohn’s Disease - EXIT-TNF

German Inflammatory Bowel Diseases Study Group, c/o Kompentenznetz chronisch entzündliche Darmerkrankungen0 sites90 target enrollmentStarted: March 25, 2014Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Not yet recruiting
Sponsor
Enrollment
90

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Observational

Eligibility Criteria

Ages
18 Years to one (—)
Sex
All

Inclusion Criteria

  • diagnosis: Crohn's disease
  • - uninterrupted treatment with adalimumab or infliximab for at least 6 months
  • - HBI <= 3
  • - planned ending of treatment with TNF blocker
  • - last dose of TNF blocker
  • * within three weeks with adalimumb
  • * within nine weeks with infliximab

Exclusion Criteria

  • - stopping of treatment because of lack of response of fistulizing disease
  • - existence of ileostomy or colostomy
  • - glucocorticoids within the last three months

Investigators

Sponsor
German Inflammatory Bowel Diseases Study Group, c/o Kompentenznetz chronisch entzündliche Darmerkrankungen

Similar Trials